These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 23229050)

  • 21. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mTOR Targets 4E-BP1/2 Restrain Tumor Growth and Promote Hypoxia Tolerance in PTEN-driven Prostate Cancer.
    Ding M; Van der Kwast TH; Vellanki RN; Foltz WD; McKee TD; Sonenberg N; Pandolfi PP; Koritzinsky M; Wouters BG
    Mol Cancer Res; 2018 Apr; 16(4):682-695. PubMed ID: 29453322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant expression and phosphorylation of 4E-BP1, a main target of mTOR signaling, in rat mammary carcinomas: an association with etiology.
    Takabatake M; Daino K; Imaoka T; Nishimura M; Morioka T; Fukushi M; Shimada Y
    In Vivo; 2011; 25(6):853-60. PubMed ID: 22021677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition.
    Dudkin L; Dilling MB; Cheshire PJ; Harwood FC; Hollingshead M; Arbuck SG; Travis R; Sausville EA; Houghton PJ
    Clin Cancer Res; 2001 Jun; 7(6):1758-64. PubMed ID: 11410517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.
    Mishra R; Miyamoto M; Yoshioka T; Ishikawa K; Matsumura Y; Shoji Y; Ichinokawa K; Itoh T; Shichinohe T; Hirano S; Kondo S
    Int J Oncol; 2009 May; 34(5):1231-40. PubMed ID: 19360336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
    Iwasaki T; Matsushita M; Nonaka D; Kuwamoto S; Kato M; Murakami I; Nagata K; Nakajima H; Sano S; Hayashi K
    Hum Pathol; 2015 Feb; 46(2):210-6. PubMed ID: 25466966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between LRRK2 and 4E-BP1 protein levels in normal and malignant cells.
    Pons B; Armengol G; Livingstone M; López L; Coch L; Sonenberg N; Ramón y Cajal S
    Oncol Rep; 2012 Jan; 27(1):225-31. PubMed ID: 21922152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer.
    Lv T; Wang Q; Cromie M; Liu H; Tang S; Song Y; Gao W
    Oncotarget; 2015 Oct; 6(32):33006-18. PubMed ID: 26360779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
    Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
    J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of phosphorylated 4E-binding protein 1 and its clinicopathological significances in gastric cancer.
    Lee HW; Park MI; Kim MS; Kim SH; Roh MS; Kim K; Jung SB; Lee EH
    Pathol Res Pract; 2015 Apr; 211(4):298-302. PubMed ID: 25661069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.
    Alain T; Morita M; Fonseca BD; Yanagiya A; Siddiqui N; Bhat M; Zammit D; Marcus V; Metrakos P; Voyer LA; Gandin V; Liu Y; Topisirovic I; Sonenberg N
    Cancer Res; 2012 Dec; 72(24):6468-76. PubMed ID: 23100465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
    Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
    Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous activation of impaired autophagy and the mammalian target of rapamycin pathway in oral squamous cell carcinoma.
    Yin X; Hu L; Feng X; Wang H; Zhang C; Wang H; Wang S
    J Oral Pathol Med; 2019 Sep; 48(8):705-711. PubMed ID: 31132188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.
    Nishikawa M; Miyake H; Behnsawy HM; Fujisawa M
    Urol Oncol; 2015 Apr; 33(4):166.e9-15. PubMed ID: 25618298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RhoE inhibits 4E-BP1 phosphorylation and eIF4E function impairing cap-dependent translation.
    Villalonga P; Fernández de Mattos S; Ridley AJ
    J Biol Chem; 2009 Dec; 284(51):35287-96. PubMed ID: 19850923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.
    Wang R; Geng J; Wang JH; Chu XY; Geng HC; Chen LB
    Lung Cancer; 2009 Nov; 66(2):237-44. PubMed ID: 19261348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.
    Gingras AC; Gygi SP; Raught B; Polakiewicz RD; Abraham RT; Hoekstra MF; Aebersold R; Sonenberg N
    Genes Dev; 1999 Jun; 13(11):1422-37. PubMed ID: 10364159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of mTOR and eIF4E expression in invasive ductal carcinoma.
    Hu A; Sun M; Yan D; Chen K
    Tumori; 2014; 100(5):541-6. PubMed ID: 25343550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines.
    Murai A; Asa SA; Kodama A; Hirata A; Yanai T; Sakai H
    BMC Vet Res; 2012 Jul; 8():128. PubMed ID: 22839755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.